Ardelyx Inc. (ARDX)
Ardelyx: Assessment Of Acquisition Rumors
Ardelyx: Assessment Of Acquisition Rumors
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Ardelyx: IBSRELA Momentum Drives Opportunity
Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemia, but its slower growth and reimbursement complexity present ongoing risk to the renal franchise.
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?
Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Ardelyx: Impressive Q3 Record Growth - Why I Buy
Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.
Ardelyx: A Long Overdue Rally
Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.
Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript
Ardelyx, Inc. ( ARDX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Christopher Raymond Joohwan Kim Roanna Ruiz Dennis Ding Thomas Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Julian Harrison - BTIG, LLC, Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Daz Patel Presentation Operator " Caitlin Lowie Vice President of Corporate Communications & Investor Relations " Michael Raab President, CEO & Director " Eric Foster Chief Commercial Officer " Justin Renz Chief Financial & Operations Officer " Christopher Raymond " Raymond James Joohwan Kim " Citi Roanna Ruiz " Leerink Partners Dennis Ding " Jefferiesruiz Thomas " Wedbush Securities Matthew Caufield H.C.
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript
Ardelyx, Inc. (NASDAQ:ARDX ) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst We're going to start the afternoon session. I'm Yigal Nochomovitz, biotech analyst at Citi.
